Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics

Abemaciclib is an oral anticancer drug that inhibits cyclin dependent kinases 4 and 6 and is metabolized by cytochrome P450 3A in the intestines and liver to active metabolites. The objectives were (1) to develop a mechanistic model to characterize the pharmacokinetics (PK) of the active moieties an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chigutsa, Emmanuel, Kambhampati, Siva Rama Prasad, Karen Sykes, Amanda, Posada, Maria M., van der Walt, Jan‐Stefan, Turner, P. Kellie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499187/
https://www.ncbi.nlm.nih.gov/pubmed/32683787
http://dx.doi.org/10.1002/psp4.12544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499187/
https://www.ncbi.nlm.nih.gov/pubmed/32683787
http://dx.doi.org/10.1002/psp4.12544

Ejemplares similares